ENVACGEN®: First EV71 Vaccine Approved in Vietnam to Combat Rising Cases

Taipei and Geneva – In a significant step toward protecting young children across Southeast Asia, Medigen Vaccine Biologics Corp. (MVC) and Substipharm Biologics have announced that ENVACGEN®, their Enterovirus 71 (EV-A71) vaccine, has received marketing authorization from the Drug Administration of Vietnam (DAV). This marks the first approval of an EV-A71 vaccine in Vietnam, a country that has experienced substantial outbreaks of the virus, and sets the stage for wider regional access through a collaboration between the two companies.

EV-A71 is a leading cause of severe neurological complications and fatalities in infants and young children throughout Asia. Vietnam, in particular, has been heavily impacted, reporting approximately 180,000 cases and 31 deaths in 2023 alone. These outbreaks place a considerable strain on the country’s healthcare system and raise serious concerns for pediatric health. The authorization of ENVACGEN® offers a crucial new tool in preventing and controlling the spread of this potentially devastating virus.

Understanding Enterovirus 71 and its Impact

Enterovirus 71 is a highly contagious virus commonly spread through close contact, respiratory droplets, and contaminated surfaces. While many infections are mild, causing symptoms like fever, mouth sores, and a rash – commonly known as hand, foot, and mouth disease (HFMD) – EV-A71 can lead to more severe complications. These include encephalitis (inflammation of the brain), meningitis (inflammation of the membranes surrounding the brain and spinal cord), and acute flaccid paralysis, a condition similar to polio. The virus’s neurotropic nature – its ability to invade the nervous system – is what makes it particularly dangerous for young children.

The 2023 outbreak in Vietnam, with over 180,000 cases, underscores the ongoing threat posed by EV-A71. Prior to the availability of a vaccine, managing these outbreaks relied heavily on public health measures like school closures and enhanced hygiene practices. However, these measures are often disruptive and may not be fully effective in containing the virus’s spread. Substipharm Biologics highlights that HFMD cases in Vietnam reached 107,249 in 2025, a 28.9% increase from the previous year, demonstrating the continued need for preventative measures.

ENVACGEN®: A “Best-in-Class” Vaccine

ENVACGEN® has demonstrated exceptional clinical performance in trials. The vaccine boasts 100% efficacy – meaning no confirmed cases occurred in the vaccinated group during the monitoring period – and provides early protection for infants as young as two months old. Importantly, the protection offered by ENVACGEN® is long-lasting, with immunogenicity maintained for over five years. This extended protection is particularly valuable in regions like Vietnam, where cyclical outbreaks are common. The vaccine’s efficacy is based on statistical analysis showing a 96.8% effectiveness rate (CI: 85.5%, 100%).

MVC, the vaccine’s developer, utilizes advanced cell culture technology and operates a bio-pharmaceutical facility certified to PIC/S GMP standards. This commitment to quality manufacturing is crucial for ensuring a reliable and consistent vaccine supply. The company received Emergency Use Authorization (EUA) during the COVID-19 pandemic, showcasing its research and development capabilities. According to a press release, MVC is already planning capacity expansion to meet the anticipated demand in Southeast Asia.

Collaboration for Regional Expansion

The partnership between MVC and Substipharm Biologics is central to the vaccine’s rollout in Vietnam and beyond. Substipharm Biologics will lead the marketing and distribution efforts in Vietnam, leveraging its established network and expertise in the region. The collaboration extends beyond Vietnam, with plans to expand access to ENVACGEN® in Thailand, the Philippines, Indonesia, Malaysia, and Singapore. This regional approach is vital for addressing the widespread threat of EV-A71 across Southeast Asia.

Substipharm Biologics brings significant experience in vaccine distribution, including the successful launch of the IMOJEV® Japanese encephalitis vaccine in 14 countries across the Asia-Pacific region. Their commitment to working with health authorities and medical professionals in Vietnam will be essential for ensuring rapid and effective vaccine deployment. BioSpectrum Asia reports that this partnership represents a milestone for both companies.

What This Means for Public Health in Vietnam

With Vietnam’s annual birth rate of 1.36 million, the availability of ENVACGEN® represents a significant opportunity to protect a large number of infants and young children from the potentially devastating effects of EV-A71. The combination of MVC’s manufacturing capacity and Substipharm Biologics’ distribution network is expected to rapidly address the unmet medical need in the region.

Leo Lee, CEO of MVC, emphasized the importance of this milestone, stating that the marketing authorization in Vietnam is a “pivotal milestone in MVC’s global expansion.” Fabrice Baschiera, CEO of Substipharm Biologics, echoed this sentiment, highlighting the long-standing challenge posed by EV-A71 in Vietnam and the commitment to delivering this innovative vaccine to the local market.

Looking Ahead: Surveillance and Continued Monitoring

The introduction of ENVACGEN® will be accompanied by ongoing surveillance to monitor its impact on EV-A71 infection rates and the severity of outbreaks. Health authorities will closely track vaccine coverage, adverse events, and the emergence of any potential viral variants. This continuous monitoring is essential for ensuring the long-term effectiveness of the vaccination program and adapting strategies as needed. Further research may also explore the potential for incorporating EV-A71 vaccination into routine childhood immunization schedules.